These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17576984)

  • 1. Progressive drug licensing: an opportunity to achieve transparency and accountability?
    Wright JM
    CMAJ; 2007 Jun; 176(13):1848-9. PubMed ID: 17576984
    [No Abstract]   [Full Text] [Related]  

  • 2. Health Canada's Progressive Licensing Framework.
    Yeates N; Lee DK; Maher M
    CMAJ; 2007 Jun; 176(13):1845-7. PubMed ID: 17576983
    [No Abstract]   [Full Text] [Related]  

  • 3. Progressive licensing needs progressive open debate.
    Hébert PC; Stanbrook M; Sibbald B; Flegel K; MacDonald N; Attaran A
    CMAJ; 2007 Jun; 176(13):1801, 1803. PubMed ID: 17576971
    [No Abstract]   [Full Text] [Related]  

  • 4. Responsibility for pharmaceutical company samples.
    Reti S
    N Z Med J; 2005 May; 118(1215):U1472. PubMed ID: 15915193
    [No Abstract]   [Full Text] [Related]  

  • 5. Health Canada targets postmarket surveillance of drugs.
    Sibbald B
    CMAJ; 2002 Jun; 166(12):1580. PubMed ID: 12074132
    [No Abstract]   [Full Text] [Related]  

  • 6. Can Health Canada protect Canadians from unsafe drugs?
    Hébert PC; Stanbrook MB; MacDonald N; Flegel K; Coutts J; MacLeod S
    CMAJ; 2011 Jul; 183(10):1125-6. PubMed ID: 21502342
    [No Abstract]   [Full Text] [Related]  

  • 7. How the FDA manages drug safety with black box warnings, use restrictions, and drug removal, with attention to gastrointestinal medications.
    Ehrenpreis ED; Ciociola AA; Kulkarni PM;
    Am J Gastroenterol; 2012 Apr; 107(4):501-4. PubMed ID: 22475958
    [No Abstract]   [Full Text] [Related]  

  • 8. Life after Vioxx.
    Underwood A
    Newsweek; 2005 Jan; 145(5):40-1. PubMed ID: 17896720
    [No Abstract]   [Full Text] [Related]  

  • 9. How the FDA handles GI drug safety.
    Lewis JH
    Am J Gastroenterol; 2012 Aug; 107(8):1264; author reply 1264-5. PubMed ID: 22859005
    [No Abstract]   [Full Text] [Related]  

  • 10. Health authorities and drug utilization studies.
    Garcia Alonso F; Scott AI; Stika L; Westerholm B
    WHO Reg Publ Eur Ser; 1993; 45():147-67. PubMed ID: 8442843
    [No Abstract]   [Full Text] [Related]  

  • 11. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 12. Barriers and Opportunities for Use of Patient Registries in Medicines Regulation.
    Olmo CA; McGettigan P; Kurz X
    Clin Pharmacol Ther; 2019 Jul; 106(1):39-42. PubMed ID: 30970160
    [No Abstract]   [Full Text] [Related]  

  • 13. The need to improve hospital investigational drug policies and procedures.
    Stolar MH
    Hosp Formul; 1983 Jan; 18(1):79-82. PubMed ID: 10258324
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse-drug-reaction monitoring.
    Faich GA
    N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current status of cosmetic product regulation].
    Pochet A
    Ann Dermatol Venereol; 2007 Mar; 134(3 Pt 2):2S46-54. PubMed ID: 17563715
    [No Abstract]   [Full Text] [Related]  

  • 16. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 17. Glaxo Wellcome withdraws irritable bowel syndrome medication.
    FDA Consum; 2001; 35(1):3. PubMed ID: 11930921
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Smith ER
    Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124
    [No Abstract]   [Full Text] [Related]  

  • 19. Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.
    Laupacis A; Paterson JM; Mamdani M; Rostom A; Anderson GM
    CMAJ; 2003 Nov; 169(11):1167-70. PubMed ID: 14638652
    [No Abstract]   [Full Text] [Related]  

  • 20. Ayerst shutdown demonstrates some patent problems with compulsory licensing.
    Garner J
    Can Pharm J; 1982 Dec; 115(12):450-2. PubMed ID: 10257839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.